Leadership Overview
Organon has 4 executives leading key functions including strategy, operations, and market development.
Driven by a commitment to improving global health, Organon focuses on developing and delivering innovative medicines that enhance the quality of human life through strategic partnerships and scientific advancement.
Driven by a commitment to improving global health, Organon focuses on developing and delivering innovative medicines that enhance the quality of human life through strategic partnerships and scientific advancement.
Leadership Roles at Organon
Angela Liu - Chief of Staff To the Chief Executive Officer
Angela Liu, the Chief of Staff To the Chief Executive Officer at Organon, provides direct strategic support and operational management for the CEO's office. Liu orchestrates critical communications and ensures the efficient execution of the CEO's agenda, bridging executive vision with organizational action. This position demands a deep understanding of Organon's business model, enabling Liu to facilitate key decisions and manage high-priority initiatives. The Chief of Staff To the Chief Executive Officer's role involves coordinating with various departments to drive progress on strategic goals, particularly in leveraging innovation and business partnerships. Angela Liu's focus is on optimizing the CEO's effectiveness and ensuring that Organon's core therapeutic fields are advanced through coordinated efforts. By managing complex projects and stakeholder relationships, Liu directly supports the company's overarching mission to improve human health and quality of life.
Mazen Altaruti - President, Emerging Markets (Japan)
Mazen Altaruti, the President, Emerging Markets (Japan) at Organon, drives the strategic direction and commercial success within key international territories. Altaruti oversees all aspects of business operations in Japan and other emerging markets, focusing on expanding Organon's reach and impact. This leadership position involves developing and executing market-specific strategies that align with the company's global mission to improve human health. The President, Emerging Markets (Japan) is responsible for fostering business partnerships and leveraging innovation to introduce Organon's prescription medicines to new patient populations. Mazen Altaruti's expertise in navigating complex regulatory environments and market dynamics ensures the effective delivery of therapeutic solutions. By leading dedicated teams and optimizing resource allocation, Altaruti significantly contributes to Organon's growth and its commitment to enhancing the quality of life worldwide.
Jo Snyder - Chief of Staff
Jo Snyder, the Chief of Staff at Organon, directs strategic initiatives and operational efficiency across the organization. Snyder ensures alignment between executive priorities and day-to-day operations, facilitating seamless communication and execution of company-wide objectives. This role involves managing key projects and supporting the leadership team in achieving Organon's mission to improve global health through innovative medicines. Snyder's oversight extends to streamlining internal processes and enhancing cross-departmental collaboration, directly contributing to the company's ability to leverage its core therapeutic fields. The Chief of Staff's responsibilities include driving critical organizational changes and ensuring that strategic plans translate into tangible business outcomes. Jo Snyder's leadership ensures that Organon's operational framework effectively supports its commitment to innovation and business partnerships, ultimately enhancing the quality of human life.
Michael Casia - Interim Head of Commercial & Government Affairs (US)
Michael Casia, the Interim Head of Commercial & Government Affairs (US) at Organon, directs the company's commercial strategies and government relations within the United States. Casia leads initiatives focused on market access, product promotion, and engagement with key stakeholders, including policymakers and healthcare providers. This critical role ensures that Organon's innovative medicines reach patients effectively while navigating the complex US healthcare landscape. The Interim Head of Commercial & Government Affairs (US) is instrumental in shaping market perception and securing favorable policy environments. Michael Casia's leadership drives revenue growth and strengthens Organon's position by fostering strong relationships with government bodies and commercial partners. By aligning commercial efforts with regulatory requirements, Casia directly supports Organon's mission to improve the health and quality of human life across the United States.
Explore Leadership Teams in Manufacturing
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer. Through sustained investment in research and development, the organization has built a comprehensive medication portfolio that combines innovative cancer immunotherapies, anticoagulant therapies, and treatments for chronic viral infections. The company's operational footprint extends across major markets worldwide, enabling efficient distribution and patient access to its therapeutic solutions. Bristol-Myers Squibb pursues a collaborative approach to medical innovation, actively engaging in research partnerships and strategic alliances that accelerate the development of new treatment options. This commitment to external collaboration complements the organization's internal capabilities, creating a dynamic environment where scientific breakthroughs can translate into meaningful therapeutic advances. Bristol-Myers Squibb's medication portfolio reflects decades of pharmaceutical expertise and a strategic focus on disease areas where unmet medical needs remain significant.
Company Leadership BT
DG
KK
USV Private Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. USV Limited was established in 1961.
Company Leadership GJ
SY
SB
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Company Leadership
RF
CW
SK
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed, and grain processors and processors; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topical and diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segments products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing,...
Company Leadership DK
KB
CD
Frequently Asked Questions Regarding Organon Top Executives and Leadership Team
